Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12, ...
PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application filed in ...
GlobalData on MSN3d
PDS Biotechnology commences trial for head and neck squamous cell carcinomaPDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on PDS Biotechnology (PDSB – Research Report) and Cartesian ...
PDS Biotechnology (NASDAQ:PDSB) said on Thursday it received U.S. FDA clearance for its Investigational New Drug application ...
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ...
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech” or the "Company”), a late-stage immunotherapy company focused on transforming how the ...
HC Wainwright restated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB – Free Report) in a research note published on Friday,Benzinga reports. They currently have a $21.00 target price on ...
PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the ...
PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback